- Home
- FTRE vs BRVE Comparison
FTRE vs BRVE Comparison
Compare FTRE & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTRE | BRVE |
|---|---|---|
| Founded | 1996 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2023 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FTRE | BRVE |
|---|---|---|
| Price | $21.06 | $21.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $22.63 | ★ $45.25 |
| AVG Volume (30 Days) | ★ 1.9M | 305.0K |
| Earning Date | 10-29-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,723,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $8.55 | $17.86 |
| 52 Week High | $26.16 | $32.00 |
Technical Indicators
Market Signals| Indicator | FTRE | BRVE |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 46.70 |
| Support Level | $16.34 | $17.93 |
| Resistance Level | $21.25 | $29.86 |
| Average True Range (ATR) | 1.36 | 1.25 |
| MACD | -0.11 | 0.41 |
| Stochastic Oscillator | 15.57 | 74.17 |
Price Performance
Historical ComparisonAbout FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
About BRVE Braveheart Bio Inc. Common Stock
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).